Treatment with nontoxic monophosphoryl lipid A (MPL) derived from a polysaccharide-deficient, heptoseless Re mutant of either Salmonella typhimurium or Salmonella minnesota R595 enhanced the immunoglobulin M (IgM) anti-type III pneumococcal polysaccharide (SSS-III) antibody response of C3H/HeSnJ mice. Such an adjuvant effect was not observed in lipopolysaccharide-nonresponder C3H/HeJ mice. Nevertheless, C3H/HeJ spleen cells produced a weak mitogenic response to both preparations of MPL in vitro, and C3H/HeJ mice showed a significant increase in serum IgM levels without an increase in numbers of splenic IgM-secreting plaque-forming cells after in vivo treatment with MPL. A significant increase in serum IgG3 levels was accompanied by a transient decrease in serum IgGl levels in C3H/HeSnJ mice given MPL; such nonantigen-specific polyclonal effects were not observed in C3H/HeJ or in athymic nulnu mice. Since the enhanced antibody response to SSS-III has been attributed to the inactivation of suppressor T cells by MPL and since suppressor-T-cell activity is demonstrable in both C3H/HeSnJ and C3H/HeJ mice, these findings imply that (i) the suppressor T cells of C3H/HeJ mice are refractory to inactivation by MPL and (ii) some of the polyclonal and mitogenic effects produced in C3H/HeJ mice are due to the direct action of MPL on B lymphocytes.
The endotoxins or lipopolysaccharides (LPSs) isolated from the cell walls of gram-negative bacteria are potent immunomodulators, mainly because they possess mitogenic activity for murine B lymphocytes in vitro, polyclonally activate murine B cells in vivo, stimulate the production of interleukin-1 (IL-1), promote granulopoiesis through the release of endogenous colony-stimulating factor, and activate macrophages (1, 2, 14, 25) . LPS enhances the immune response when injected with an antigen (20, 31) and suppresses or enhances it when injected before an antigen (9, 26) . LPS also induces the production of tumor necrosis factor, which has antitumor activity (10) . All of these various immunomodulatory activities are elicited by the diphosphoryl lipid A portion of the LPS molecule (for a review, see reference 24), which is extremely toxic and pyrogenic for most animal species, thereby precluding its use as a therapeutic agent; however, the removal of a phosphate group from the reducing end of diphosphoryl lipid A yields monophosphoryl lipid A MPL (N. Qureshi and K. Takayama, in B. H. Iglewski and V. L. Clark, ed., Molecular Basis of Bacterial Pathogenesis, in press). Since MPL retains all of the immunomodulatory properties of LPS and diphosphoryl lipid A but is significantly less toxic and pyrogenic (30) , it can safely be used as an adjuvant in vivo.
We have shown that MPL increases the antibody response to type III pneumococcal polysaccharide (SSS-III) by abrogating the activity of suppressor T (TJ) cells without influencing helper-T-cell (TH) and amplifier-T-cell function (5) . MPL has been shown to be mitogenic for the spleen cells of LPS-responsive (LPS') and LPS-defective (LPSd) mice (36) and to increase the antibody response of C3H/HeJ mice to sheep erythrocytes (37) . The present study was Antigen and immunization procedure. The immunological properties of the preparation of SSS-III used and the method by which it was prepared have been described (7) . For immunization, mice were given a single intraperitoneal (i.p.) injection of an optimally immunogenic dose (500 ng) of SSS-III. The magnitude of the antibody response produced was determined 5 days after immunization.
Detection of antibody-secreting cells. The numbers of splenic antibody-producing plaque-forming cells (PFC) making antibody specific for SSS-III provided a measure of the antibody response elicited in individual mice 5 days after immunization with SSS-III, i.e., at the peak of the antibody response. PFC making antibody of the immunoglobulin M (IgM) class (>90% of all PFC found [6] ) were detected by a slide version of the localized hemolysis-in-gel technique, using indicator sheep erythrocytes coated with SSS-III by the CrCl3 method (8) . Corrections were made for numbers of background sheep-erythrocyte-specific PFC found, so that only PFC making antibody specific for SSS-III were considered. The values obtained (PFC per spleen), which are log normally distributed (15) , are expressed as the geometric mean (antilog) of the log1o number of PFC per spleen for groups of similarly treated mice. This provides a reasonably good measure of the magnitude of the total antibody response produced since SSS-III-specific PFC are detected only in the spleens of immunized mice (21) .
Cells secreting non-antigen-specific immunoglobulin of the IgM class were detected by a slide version of the protein A plaque assay (5, 16 Spleen cell suspensions were prepared and cultured in 96-well flat-bottom microtiter plates (Costar, Cambridge, Mass.) as described previously (5) . During the last 6 h of culture, 1 ,uCi of [methyl-3H]thymidine (Dupont, NEN Research Products, Boston, Mass.; specific activity 6.7 Ci/ mmol) was added. Then, the cells were harvested by means of a PHD cell harvester (Cambridge Technology, Watertown, Mass.) and collected on glass fiber filters. Radioactivity was detected with a scintillation counter (model LS8100; Beckman Instruments, Inc., Fullerton, Calif.).
Serum immunoglobulin levels. The levels of various serum immunoglobulins were determined for individual mice by an enzyme-linked immunosorbent assay. IgM levels were determined by the overnight coating of Immulon I microtiter plates (Dynatech Industries, Inc., Chantilly, Va.) with 100 ng of goat anti-mouse IgM (lot H247; Southern Biotechnology, Inc., Birmingham, Ala.) at 4°C. The plates were washed with a solution of 0.15 M NaCl containing 0.05% Tween 20 and blocked for 45 min at 37°C with phosphate-buffered saline containing 10% fetal bovine serum. After the plates were washed, serial twofold dilutions of serum sample or mouse immunoglobulin standards (50 pul per well) were added and allowed to react for 90 min at 37°C. The plates then were washed, and 100 ,ul of an optimal dilution of horseradish peroxidase-labeled goat anti-mouse IgM (lot C8-P948; Southern Biotechnology, Inc.) was added. The plates were incubated for 90 min at 37°C and then washed. Color was developed by the addition of a solution containing an equal volume of peroxidase substrate solution A (ABTS) and peroxidase substrate solution B (hydrogen peroxide) (Kirkegaard and Perry Laboratories, Gaithersburg, Md.). The enzymatic reaction was stopped by the addition of 100 ,ul of peroxidase "stop solution" (Kirkegaard and Perry Laboratories) per well, and the plates were read on an MR600 plate reader (Dynatech) with a 410-nm test wavelength and a 490-nm reference wavelength. The same method was used to determine the levels of the various subclasses of serum IgG, as well as serum IgA levels. For subclasses of serum IgG, the plates were coated with 100 ng of goat anti-mouse IgG (lot A148) and 100 ,u1 of an optimal dilution of horseradish peroxidase-labeled goat anti-mouse IgGl (lot D8-R218), goat anti-mouse IgG2a (lot J7-X007), goat anti-mouse IgG2b (lot I7-W067), or goat anti-mouse IgG3 (lot A8-P958) was added to determine the serum level of each corresponding subclass of IgG. For the determination of serum IgA levels, plates were coated with 100 ng of goat anti-mouse IgA (lot C148), followed by the addition of 100 ,ul of an optimal dilution of horseradish peroxidaselabeled goat anti-mouse IgA (lot K6-P047). The reagents were purchased from Southern Biotechnology, Inc. The results obtained are expressed as the log1o (micrograms of immunoglobulin per milliliter of serum) (mean + SEM).
Immunomodulating agents. LPSs from Escherichia coli 0113 (LPS 0113) and Salmonella minnesota R595 (LPS R595), MPL (average molecular weight, 1,718), and trehalose dimycolate (TDM; average molecular weight, 2,860) isolated from Mycobacterium phlei were obtained from Ribi ImmunoChem Research, Inc., Hamilton, Mont. LPS 0113 was extracted by the phenol-water method (40) , and LPS R595 was extracted by the procedure of Galanos et al. (13) . Because of the extraction procedures used, these Qureshi and Takayama, in press). Lyophilized MPL was reconstituted to 1 mg/ml in distilled water containing 0.2% triethylamine. It was mixed thoroughly and sonicated briefly to obtain an opalescent stock solution which was stored at 4°C until use. Data on the toxicity and pyrogenicity of MPL, as well as on the parent LPS from which they were derived, have been published (29) . Lyophilized TDM was solubilized in a mixture of chloroform and methanol (9:1) to a concentration of 10 mg/ml and dried under vacuum. Then, TDM was emulsified in 400 ,ul of squalene oil (Sigma Chemical Co., St. Louis, Mo.) and adjusted to a concentration of 500 ,ug/ml in saline containing 0.2% Tween 80. This stock solution was stored at 4°C until use.
Statistics. Student's t test was used to evaluate the significance of the differences observed. Differences were considered to be significant when probability (P) values <0.05 were obtained. (36, 38) (17) , and to LPS R595, which is mitogenic for LPSd spleen cells (36) , also were examined and used as controls.
RESULTS

Mitogenic activities of MPL(ST) and MPL(SM). Previous studies
Effect of MPL(ST) on serum immunoglobulin levels. MPL, which is a potent mitogen for B lymphocytes in vitro, is also a polyclonal activator of B cells in vivo (5) . Since polyclonal B-cell activation causes an increase in the number of IgMand IgG-secreting B lymphocytes (11) , as well as an increase in serum immunoglobulin levels, we examined the serum immunoglobulin levels of mice treated with MPL. The serum IgM levels of both nulnu and nul+ mice increased significantly after treatment with MPL(ST) ( (19) showed that in mice treated with LPS R595, there is a rapid increase in serum IgM levels and a delayed increase in serum IgG levels, we also examined serum immunoglobulin levels of C3H mice 12 days after the treatment with MPL(ST). We found a significant increase (P < 0.05) in the serum IgGl, IgG2b, and IgG3 levels and no significant increase (P > 0.05) in the serum IgM, IgG2a, and IgA levels of C3H/HeSnJ mice treated with MPL (Table 3) . Thus, although we detected an initial decrease in the level of serum IgGl in C3H/HeSnJ mice 3 days after treatment with MPL (Table 2) , an increase was noted 12 days after the administration of MPL. The increased levels of serum IgG2b observed at day 12 were not noted 3 days after the treatment with MPL. C3H/HeJ mice treated with MPL(ST) showed no significant differences (P > 0.05) in serum immunoglobulin levels 12 days after the treatment (data not shown).
Adjuvant activity of MPL in nude mice. MPL(ST) does not increase the magnitude of the SSS-Ill-specific antibody (PFC) response of nude mice, even though it induces significant polyclonal activation of IgM synthesis (5). Consequently, we wished to examine the effects of MPL(SM) on both the antigen-specific and polyclonal IgM responses of nude mice. MPL(SM) and MPL(ST) both induced a significant (P < 0.001) polyclonal IgM response in nulnu and nul+ mice, as evidenced by the increased numbers of IgMsecreting PFC detected (Table 4) . MPL(ST) had no effect (P > 0.05) on the magnitude of the SSS-III-specific PFC response of nulnu mice, as reported previously (5); however, MPL(SM) significantly (P < 0.05) increased the SSS-IIIspecific PFC response of nulnu mice. Although the basis for this difference is not known, it might be related to the stronger polyclonal (Table 4) (Tables 5 and 6 ; P < 0.01). In C3H/HeJ mice, neither type of MPL had a significant effect (P > 0.05) on the numbers of SSS-III-specific and IgM-secreting PFC detected (Tables 5 and 6 ); this seems to be at variance with the data in Table 2 showing an increase in the levels of serum IgM observed for C3H/HeJ mice treated with MPL(ST). This might be due to inherent differences between the two methods used. Even though serum IgM levels are a reflection of the activity of MPL(ST) in vivo in various organs between the time of its injection and the time of bleeding, the assay for IgM-secreting PFC determines the number of IgM-secreting 13 lymphocytes present in the spleen at the time of sacrifice. Thus, for C3H/HeJ mice, both types of MPL were mitogenic for spleen cells in vitro (Table 1) and polyclonally stimulated B lymphocytes in vivo in one of the assays used (Table 2) ; however, they had no detectable effect on the magnitude of the antibody response to SSS-III, thereby indicating a dissociation between these phenomena.
Previous studies suggest that MPL(ST) increases the magnitude of the SSS-III-specific antibody response by inactivating T1 cells (5) . The failure to augment the antibody response to SSS-III in C3H/HeJ mice, in conjunction with the absence of appreciable B-cell polyclonal activation by MPL, suggests that both processes may be under common genetic control and involve the absence of a cell receptor required for the binding of MPL. In order to evaluate the degree of Ts function in C3H/HeJ and C3H/HeSnJ mice, animals of both strains were given 5 ng of SSS-IlI 3 days before immunization with an optimal immunogenic dose of 500 ng; this results in the development of low-dose paralysis, a form of antigen-specific unresponsiveness known to be mediated by T5 cells (3, 35) . In BALB/c mice, the expression of low-dose paralysis can be abrogated by treatment with MPL (5) . The data in Table 7 show that C3HIHeJ and C3H/HeSnJ mice did not differ in the degree of low-dose paralysis induced, indicating that they do not differ with respect to T. function; however, low-dose paralysis was abrogated in C3H/HeSnJ mice (group B versus group C, P < 0.001) but not in C3H/HeJ mice (group E versus group F, P > 0.05) treated with MPL(ST).
Adjuvant activity of TDM in C3H mice. The data presented
in Tables 5 and 6 show that MPL cannot significantly increase the anti-SSS-III splenic PFC response of C3H/HeJ mice. In order to be sure that this does not reflect a general inability of C3H/HeJ mice to respond to the effects of any bacterial adjuvant, we examined the ability of TDM to influence the antibody response to SSS-Ill in C3H/HeJ mice; tions of MPL and strains of mice which differ greatly in their capacity to respond to LPS were used in the experiments. Both MPL(ST) and MPL(SM) stimulated a proliferative response by spleen cells of LPSd C3H/HeJ mice in vitro (Table 1) ; such mice also showed increased serum IgM levels following treatment with MPL(ST), thereby reflecting the capacity of MPL to act in vivo in LPSd mice (Table 2 ). These data extend previous reports (34, 36, 38, 39) showing that lipid A-rich molecules are able to activate LPSd spleen cells. One interpretation is that C3H/HeJ spleen cells are unable to respond to the stimulus of native (polysaccharide-rich) LPS because they cannot process it into smaller lipid A-rich molecules which are able to signal LPSd spleen cells (36, 38) . This interpretation is compatible with the fact that LPSd and LPSr spleen cells have comparable ability to bind LPS (22) , since processing mnay be consequent to binding. Nevertheless, increased numbers of SSS-III-specific and IgM-secreting PFC were not detected in the spleens of MPL-treated C3H/HeJ mice, although such increases were noted in responsive (LPSr) C3H/HeSnJ mice (Tables 5 and 6 ). Although this apparent lack of polyclonal B-cell activation appears to be at variance with the increased levels of serum IgM found, it might simply be due to certain variables and inherent differences in the assay procedures used. In this context, the assay used to detect numbers of IgM-secreting PFC provides information on the number of all spleen cells engaged in non-antigen-specific IgM synthesis at a given point in time, whereas determination of serum immunoglobulin levels reflects the cumulative production of immunoglobulin during a time span of several days prior to assay. Furthermore, the latter would be greatly influenced by (i) the synthesis and/or secretion of IgM at sites other than the spleen, (ii) a slight but steady increase in the number of IgM-secreting PFC after the injection of MPL, and (iii) changes in the rate of secretion and/or catabolism of IgM, but not necessarily numbers of IgM-secreting cells, in mice treated with MPL. Obviously, this issue requires further investigation.
Although MPL-treated C3H/HeJ mice had elevated serum IgM levels, they did not shown significant increases in serum IgG3 levels, as noted for C3H/HeSnJ mice treated with MPL ( Table 2 ). This could have been due to the weaker proliferative response induced by MPL in C3H/HeJ spleen cells (Table 1) , since the induction by LPS of a switch from IgM to IgG3 synthesis in vitro requires extensive cell proliferation (32) . If this is also the case in vivo, it could account for the absence of increased serum IgG3 levels in MPL-treated C3H/HeJ mice; however, increased serum IgG3 levels were detected in nul+ but not nulnu mice (Table 2 ). Since both nulnu and nul+ mice showed increased serum IgM levels after treatment with MPL, this suggests greater T-cell dependence for MPL-induced IgG3 secretion. We also noticed a decrease in the serum IgGl levels of C3H/HeSnJ and nul+ mice 3 days after the treatment with MPL ( (Tables  2 and 3 ). Since the production of IgGl can be stimulated by IL-4, which is produced by TH2 cells (18, 33) , further studies should enable one to determine whether this is due to a negative influence of MPL on the production of IL-4 and/or the interaction of IL-4 with B lymphocytes soon after treatment with MPL. For example, MPL could affect TH2 cells by inducing the production of gamma interferon by THi cells; gamma interferon has been shown to have a negative effect on the proliferation of TH2 cells (12) . It should be noted that, although the genetic defect of C3H/HeJ mice prevents them from responding in the same manner as C3H/HeSnJ mice to the adjuvant effect of MPL, it does not alter their capacity to respond to other immunomodulating agents. TDM, an adjuvant molecule derived from M. phlei, increased the magnitude of the SSS-III-specific antibody response in C3H/HeJ mice, as well as in C3H/HeSnJ mice (Table 8 ). This suggests that the B cells of both strains of mice are receptive to stimulation by adjuvants and that the mechanisms involved in producing the adjuvant effects by MPL and TDM may differ.
